Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Computing & Software
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Sumitomo Pharma Co., Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that the company patent portfolio is being reviewed by multiple officials in different administrative divisions of the USPTO. The 2 distinct art units suggest that the pending matters cover different technical aspects of biotechnology or pharmaceuticals.
SONG, JIANFENG is the busiest examiner for this portfolio, currently managing 1 pending office action. Since there are 2 pending office actions and 2 distinct examiners, each of the 2 distinct examiners is responsible for 1 pending office action. The 2 distinct art units provide a varied environment for prosecution, requiring practitioners to adapt to different unit-specific standards. This profile reflects a diversified approach to securing patent rights across the 2 pending office actions in the biotech sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SONG, JIANFENG | 1 | 56.3% | +33.2% |
| LEVERETT, MARY CHANG | 1 | 60.2% | +20.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549967 | PREDICTION OF AMOUNT OF IN VIVO DOPAMINE ETC., AND APPLICATION THEREOF | LEVERETT, MARY CHANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18723166 | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING BICYCLIC BACKBONE | SONG, JIANFENG | 15d overdue |
| 18549967 | PREDICTION OF AMOUNT OF IN VIVO DOPAMINE ETC., AND APPLICATION THEREOF | LEVERETT, MARY CHANG | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 2123 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18723166 | 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING BICYCLIC BACKBONE | SONG, JIANFENG | 1613 | §112 | Final Rejection | 15d overdue | Pending | Jun 21, 2024 |
| 18549967 | PREDICTION OF AMOUNT OF IN VIVO DOPAMINE ETC., AND APPLICATION THEREOF | LEVERETT, MARY CHANG | 2123 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial